natgillin/translations-raw huggingface dataset:
Talk to your doctor who will decide if you can breastfeed your baby or not, and if it is necessary to stop Sevelamer carbonate Winthrop treatment. 
Obratite se svom liječniku koji će odlučiti možete li dojiti svoje dijete ili ne, te da li je potrebno prekinuti liječenje lijekom Sevelamer carbonate Winthrop..
OTHER SPECIAL WARNING, IF NECESSARY EXPIRY DATE 
DRUGO(A) POSEBNO(A) UPOZORENJE(A), AKO JE POTREBNO ROK VALJANOSTI
Difficulties swallowing the Sevelamer carbonate Winthrop tablet have been reported. 
Prijavljene su poteškoće s gutanjem Sevelamer carbonate Winthrop tableta.
It is recommended that CKD patients not on dialysis are given vitamin D supplements (approximately 400 IU of native vitamin D daily) which can be part of a multivitamin preparation to be taken apart from their dose of sevelamer carbonate. 
(približno 400 IU nativnog vitamina D dnevno), koji mogu biti dio multivitaminskog pripravka koji se mora uzimati odvojeno od doze sevelamerkarbonata.
This medicine does not require any special temperature storage conditions. 
Lijek ne zahtijeva posebne temperaturne uvjete čuvanja.
What you need to know before you take Sevelamer carbonate Winthrop 3. 
Što morate znati prije nego što počnete uzimati Sevelamer carbonate Winthrop
Sevelamer hydrochloride, which contains the same active moiety as sevelamer carbonate, has been given to normal healthy volunteers in doses of up to 14 grams per day for eight days with no adverse reactions. 
Sevelamerklorid, koji sadrži istu djelatnu tvar kao sevelamerkarbonat, bio je davan zdravim dobrovoljcima u dozama do 14 grama na dan tijekom osam dana, bez razvoja nuspojava.
In the 12 week study involving peritoneal dialysis patients however, similar iPTH reductions were seen compared with patients receiving calcium acetate. 
U 12-tjednom ispitivanju koje je uključivalo bolesnike na peritonejskoj dijalizi, uočena su slična smanjenja vrijednosti iPTH-a kao u bolesnika koji su primali kalcijev acetat.
Stopping Sevelamer carbonate Winthrop would lead to important consequences such as calcification in the blood vessels. 
Prekid uzimanja lijeka Sevelamer carbonate Winthrop bi dovest će do ozbiljnih posljedica kao što je otvrdnuće krvnih žila.
The powder may also be pre-mixed with cold beverage or unheated food (see 4.2). 
Prašak se također prethodno može pomiješati s hladnim pićem ili hranom koja nije zagrijana (vidjeti
A 0,4 g dosing spoon is provided in the carton. 
Dozirna žličica za odmjeravanje 0,4 g je priložena u kutiji.
Sevelamer carbonate Winthrop film-coated tablets are white to off-white tablets with SC800 imprinted on one side. 
Sevelamer carbonate Winthrop filmom obložene tablete su bijele tablete, s otisnutom oznakom SC800
Caution should be exercised when prescribing PPI to patients concomitantly treated with Sevelamer carbonate Winthrop. 
Potreban je oprez pri propisivanju inhibitora protonske pumpe bolesnicima koji su istovremeno liječeni lijekom Sevelamer carbonate Winthrop.
• if you experience severe abdominal pain, stomach or intestine disorders, or blood in the stool (gastrointestinal bleeding). 
• osjetite jaku bol u trbuhu, poremećaje želuca ili crijeva ili krv u stolici (gastrointestinalno krvarenje).
• if you have active inflammation of the bowel 
• imate aktivnu upalu crijeva
Children and adolescents (>6 years of age and a BSA of >0.75m2) For paediatric patients, serum phosphorus levels must be monitored and the dose of sevelamer carbonate titrated in increments based on patient's BSA, three times per day every 2-4 weeks until an acceptable serum phosphorus level is reached, with regular monitoring thereafter. 
Djeca i adolescenti (>6 godina starosti i površine tijela >0,75 m2) Za pedijatrijske bolesnike, razine fosfora u serumu moraju se pratiti i doza sevelamerkarbonata titrirati u koracima temeljenim na bolesnikovoj površini tijela, tri puta dnevno svaka 2 do 4 tjedna dok se ne postigne prihvatljiva razina fosfora u serumu, s redovitim praćenjem nakon toga.
In patients not taking supplemental folic acid but on sevelamer, folate level should be assessed regularly. 
Ako bolesnici ne uzimaju nadomjestke folatne kiseline, a liječe se sevelamerom, potrebno je redovno pratiti razinu folata.
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING LABEL - SACHETS 
PODACI KOJI SE MORAJU NALAZITI NA UNUTARNJEM PAKIRANJU NALJEPNICA - VREĆICE
The safety and efficacy of Sevelamer carbonate Winthrop in children below the age of 6 years or in children with a BSA (Body Surface Area) below 0.75 m2 have not been established. 
Sigurnost i djelotvornost lijeka Sevelamer carbonate Winthrop u djece mlađe od 6 godina ili u djece s površinom tijela ispod 0,75 m2 nisu ustanovljene.
- Serious inflammation of the large bowel (symptoms include: severe abdominal pain, stomach or intestine disorders, or blood in the stool [gastrointestinal bleeding]) and crystal deposit in the intestine have been reported. 
- ozbiljna upala debelog crijeva (simptomi uključuju: jaku bol u trbuhu, poremećaje želuca ili crijeva ili krv u stolici [krvarenje u crijevima]) te nakupljanje kristala u crijevima su prijavljeni.
Each tablet contains 800 mg sevelamer carbonate. 
Jedna tableta sadrži 800 mg sevelamerkarbonata.
Sevelamer carbonate Winthrop contains the active substance sevelamer carbonate. 
Sevelamer carbonate Winthrop sadrži djelatnu tvar sevelamerkarbonat.
There was no increased incidence of tumors observed in mice (human equivalent dose 3 times the maximum clinical trial dose). 
Nije uočena povećana incidencija tumora kod miševa (pri dozi koja je odgovarala trostrukoj najvišoj dozi za ljude u kliničkim ispitivanjima).
EU/1/14/952/002 60 sachets EU/1/14/952/003 90 sachets 
EU/1/14/952/002 60 vrećica EU/1/14/952/003 90 vrećica
The safety and efficacy of sevelamer carbonate have not been established in adult patients with chronic kidney disease not on dialysis with serum phosphorus < 1.78 mmol/l. 
Nisu ustanovljene sigurnost i djelotvornost sevelamerkarbonata u odraslih bolesnika s kroničnom bubrežnom bolešću koji nisu na dijalizi, a koji imaju razinu fosfora u serumu < 1,78 mmol/l.
Sanofi-Aventis Deutschland GmbH Tel: +49 (0)180 2 222010 
Zentiva Pharma GmbH Tel: +49 (0)180 2 222010
Sevelamer carbonate Winthrop 800 mg film-coated tablets 
Sevelamer carbonate Winthrop 800 mg filmom obložene tablete
Talk to your doctor who will decide if you can continue the treatment with Sevelamer carbonate Winthrop. 
Obratite se svom liječniku koji će odlučiti hoćete li nastaviti liječenje lijekom Sevelamer carbonate Winthrop.
Dialysis 
Dojenje
The treatment response during the 2-week FDP was not affected by BSA, in contrast however, no treatment response was observed in pediatric patients with qualifying phosphorus levels <7.0 mg/dL. 
Površina tijela nije utjecala na odgovor na liječenje tijekom 2 tjedna razdoblja fiksne doze, te je nasuprot tome, izostanak odgovora na liječenje zabilježen u pedijatrijskih bolesnika s početnom vrijednosti fosfora <7,0 mg/dL.
If you forget to take Sevelamer carbonate Winthrop 
Ako ste zaboravili uzeti Sevelamer carbonate Winthrop
27% of paediatric patients reached their age appropriate serum phosphorus level at end of treatment. 
pedijatrijskih bolesnika dostiglo je razinu fosfora u serumu prikladnu za dob.
Sevelamer carbonate Winthrop contains sevelamer, a non-absorbed phosphate binding crosslinked polymer. 
Sevelamer carbonate Winthrop sadrži sevelamer, neapsorbirajući umreženi polimer koji veže fosfate.
Your doctor will check for interactions between Sevelamer carbonate Winthrop and other medicines on a regular basis. 
Liječnik će redovito provjeravati jesu li nastupile interakcije između lijeka Sevelamer carbonate
In two randomised, cross over clinical trials, sevelamer carbonate has been shown to be therapeutically equivalent to sevelamer hydrochloride and therefore effective in controlling serum phosphorus in CKD patients on haemodialysis. 
U dva randomizirana ukrižena klinička ispitivanja dokazano je da je sevelamerkarbonat terapijski ekvivalentan sevelamerkloridu, što znači da učinkovito kontrolira koncentracije fosfora u serumu u bolesnika s kroničnom bubrežnom bolešću koji su na hemodijalizi.
For a 2.4 g dose, the powder for oral suspension should be dispersed in 60 ml of water per sachet. 
Doza od 2,4 g praška za oralnu suspenziju iz jedne vrećice se prije primjene mora rastopiti u 60 ml vode.
If you stop taking Sevelamer carbonate Winthrop 
Ako prestanete uzimati Sevelamer carbonate Winthrop
• adult patients with chronic (long-term) kidney disease who are not on dialysis and have a serum (blood) phosphorus level equal to or above 1.78 mmol/l. 
• odraslih bolesnika s kroničnom (dugotrajnom) bubrežnom bolešću koji nisu na dijalizi i imaju razinu fosfora u serumu (krvi) jednaku ili višu od 1,78 mmol/l.
90 sachets per carton 
90 vrećica u kutiji
• Thyroid hormone deficiency may uncommonly be observed in certain people taking levothyroxine (used to treat low thyroid hormone levels) and Sevelamer carbonate Winthrop. 
• U nekih osoba koje uzimaju levotiroksin (koji se koristi za liječenje niskih razina hormona štitnjače) i Sevelamer carbonate Winthrop manje često može doći do nedostatka hormona štitnjače.
Talk to your doctor while taking Sevelamer carbonate Winthrop: 
Obratite se svom liječniku ako tijekom uzimanja Sevelamer carbonate Winthrop:
Package leaflet: Information for the user Sevelamer carbonate Winthrop 800 mg film-coated tablets sevelamer carbonate 
Uputa o lijeku: Informacije za korisnika Sevelamer carbonate Winthrop 800 mg filmom obložene tablete sevelamerkarbonat
The first study demonstrated that sevelamer carbonate tablets dosed three times per day was equivalent to sevelamer hydrochloride tablets dosed three times per day in 79 haemodialysis patients treated over two randomised 8 week treatment periods (mean serum phosphorus time-weighted averages were 1.5 ± 0.3 mmol/L for both sevelamer carbonate and sevelamer hydrochloride). 
U prvom je ispitivanju dokazano da je primjena tableta sevelamerkarbonata tri puta na dan bila jednako učinkovita kao primjena tableta sevelamerklorida tri puta na dan u 79 bolesnika na hemodijalizi liječenih tijekom dva nasumična 8-tjedna razdoblja liječenja (prosjek srednjih vrijednosti serumskog fosfora, uzimajući u obzir vrijeme liječenja, bio je 1,5 ± 0,3 mmol/l i kod primjene sevelamerkarbonata i kod primjene sevelamerklorida).
• patients with chronic (long-term) kidney disease who are not on dialysis and have a serum (blood) phosphorus level equal to or above 1.78 mmol/L. 
• bolesnika s kroničnom (dugotrajnom) bubrežnom bolešću koji nisu na dijalizi i imaju razinu fosfora u serumu (krvi) jednaku ili višu od 1,78 mmol/l.
Check with your doctor, pharmacist or nurse if you are not sure. 
Ako niste sigurni, obratite se Vašem liječniku, ljekarniku ili medicinskoj sestri.
Sevelamer carbonate Winthrop 800 mg film-coated tablets sevelamer carbonate 
Sevelamer carbonate Winthrop 800 mg filmom obložene tablete sevelamerkarbonat
Sevelamer carbonate treatment should be reevaluated in patients who develop severe constipation or other severe gastrointestinal symptoms. 
Liječenje sevelamerkarbonatom treba se ponovo procijeniti u bolesnika koji razviju tešku konstipaciju ili druge teške gastrointestinalne simptome.
• if you have bowel obstruction 
• ako patite od blokade crijeva
(Instructions for presentation WITH dosing spoon) To achieve the correct dose, the dosing spoon provided in the carton must be used to measure 0.4 g of Sevelamer carbonate Winthrop. 
Kako bi se postigla ispravna doza mora se upotrijebiti dozirna žličica koja je priložena u kutiji kako bi se izmjerilo 0,4 g Sevelamer carbonate Winthrop praška.
Treatment of these patients with Sevelamer carbonate Winthrop should only be initiated after careful benefit/risk assessment. 
• velikim operativnim zahvatom u gastrointestinalnom traktu Liječenje tih bolesnika lijekom Sevelamer carbonate Winthrop treba započeti tek nakon pomne procjene omjera koristi i rizika.
How to take Sevelamer carbonate Winthrop 
Kako uzimati Sevelamer carbonate Winthrop
• upper abdominal pain, 
• bol u gornjem dijelu trbuha,
EU/1/14/952/005 90 sachets EU/1/14/952/006 90 sachets (with a dosing spoon) 
EU/1/14/952/006 90 vrećica (sa dozirnom žličicom)
For adult patients, serum phosphorus must be monitored and the dose of sevelamer carbonate titrated by 0.8 g three times per day (2.4 g/day) increments every 2-4 weeks until an acceptable serum phosphorus level is reached, with regular monitoring thereafter. 
Za odrasle bolesnike, razine fosfora u serumu moraju se pratiti i doza sevelamerkarbonata titrirati u koracima od 0,8 g tri puta na dan (2,4 g/dan) svaka 2 do 4 tjedna dok se ne postigne prihvatljiva razina fosfora u serumu s redovitim praćenjem nakon toga.
Sevelamer carbonate Winthrop is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease (CKD) not on dialysis with serum phosphorus > 1.78 mmol/L. 
Sevelamer carbonate Winthrop je indiciran i za kontrolu hiperfosfatemije u odraslih bolesnika s kroničnom bubrežnom bolešću koji nisu na dijalizi, a koji imaju razinu fosfora u serumu > 1,78 mmol/l.
Package leaflet: Information for the user Sevelamer carbonate Winthrop 0.8 g powder for oral suspension sevelamer carbonate 
Uputa o lijeku: Informacije za korisnika Sevelamer carbonate Winthrop 0,8 g prašak za oralnu suspenziju sevelamerkarbonat
Package leaflet: Information for the user Sevelamer carbonate Winthrop 2.4 g powder for oral suspension sevelamer carbonate 
Uputa o lijeku: Informacije za korisnika Sevelamer carbonate Winthrop 2,4 g prašak za oralnu suspenziju sevelamerkarbonat
The safety and efficacy of Sevelamer carbonate Winthrop in children over 6 year of age and a BSA >0.75 m2 have been established. 
Sigurnost i djelotvornost lijeka Sevelamer carbonate Winthrop u djece starije od 6 godina i s površinom tijela iznad 0,75m2 su ustanovljene.
- Blockage in the intestine (signs include: severe bloating; abdominal pain, swelling or cramps; severe constipation) has been reported. 
- blokada crijeva (znakovi uključuju: jaku nadutost, bol u trbuhu, oticanje ili grčeve, teški zatvor) je zabilježena.
Hepatic impairment No studies have been performed in patients with hepatic impairment. 
Nisu provedena ispitivanja u bolesnika s oštećenjem funkcije jetre.
Powder for oral suspension 0.8 g powder 
Prašak za oralnu suspenziju 0,8 g sevelamerkarbonata
The powder should be dispersed in 60 ml of water per sachet prior to administration. 
Prašak iz jedne vrećice mora se prije primjene rastopiti u 60 ml vode.
The safety and effectiveness of sevelamer carbonate in hyperphosphatemic paediatric patients with CKD was evaluated in a multicenter study with a 2-week, randomised, placebo-controlled, fixed dose period (FDP) followed by a 6-month, single-arm, open-label, dose titration period (DTP). 
Sigurnost i učinkovitost sevelamerkarbonata u hiperfosfatemičnih pedijatrijskih bolesnika s kroničnom bubrežnom bolesti procijenjene su u multicentričnom ispitivanju s dvotjednim, randomiziranim,
The powder should be dispersed in 30 mL of water per sachet prior to administration. 
Prašak iz jedne vrećice mora se prije primjene rastopiti u 30 ml vode.
Sevelamer carbonate Winthrop should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease. 
Sevelamer carbonate Winthrop treba primjenjivati u sklopu multiterapijskog pristupa, koji može uključivati nadomjestke kalcija i 1,25-dihidroksi vitamin D3 ili neki od njegovih analoga, kako bi se kontrolirao razvoj bubrežne osteodistrofije.
How to store Sevelamer carbonate Winthrop 
Kako čuvati Sevelamer carbonate Winthrop
- Rupture in the intestinal wall (signs include: severe stomach pain, chills, fever, nausea, vomiting, or a tender abdomen) has been reported. 
- blokada crijeva (znakovi uključuju: jaku nadutost, bol u trbuhu, oticanje ili grčeve, teški zatvor) je bila zabilježena.
Sevelamer carbonate Winthrop 2.4 g powder for oral suspension 
Sevelamer carbonate Winthrop 2,4 g prašak za oralnu suspenziju
Sevelamer carbonate Winthrop 0.8 g powder for oral suspension 
Sevelamer carbonate Winthrop 0,8 g prašak za oralnu suspenziju
Sevelamer carbonate Winthrop 2.4 g powder for oral suspension sevelamer carbonate 
Sevelamer carbonate Winthrop 2,4 g prašak za oralnu suspenziju sevelamerkarbonat
The study met its primary endpoint, meaning Sevelamer carbonate reduced serum phosphorus by an LS mean difference of 0.90 mg/dL compared to placebo and secondary efficacy endpoints. 
Ispitivanje je postiglo mjeru primarnog ishoda, što znači da je sevelamerkarbonat smanjio razinu fosfora u serumu za srednju vrijednost (dobivenu metodom najmanjih kvadrata) razlike od 0,90mg/dL
- The other ingredients are propylene glycol alginate (E405), citrus cream flavour, sodium chloride, 
Drugi sastojci su propilenglikolalginat (E405), aroma kreme od citrusa, natrijev klorid, sukraloza i žuti željezov oksid (E172).
Sevelamer carbonate Winthrop 0.8 g powder for oral suspension sevelamer carbonate 
Sevelamer carbonate Winthrop 0,8 g prašak za oralnu suspenziju sevelamerkarbonat
• dysphagia 
• mučnina
In some cases where Sevelamer carbonate Winthrop should be taken at the same time as another medicine, your doctor may advise you to take this medicine 1 hour before or 3 hours after Sevelamer carbonate Winthrop intake. 
liječnik Vam može preporučiti da taj lijek uzmete 1 sat prije ili 3 sata nakon uzimanja lijeka Sevelamer carbonate Winthrop.
It can be an early symptom of a blockage in your intestine. 
Zatvor je vrlo česta nuspojava, a može biti rani simptom blokade crijeva.
Propylene glycol alginate (E405) Citrus Cream flavour Sodium chloride Sucralose 
6.1 Popis pomoćnih tvari propilenglikolalginat (E405) aroma kreme od citrusa natrijev klorid sukraloza željezov oksid, žuti (E172)
• flatulence. 
• proljev,
• The effects of medicines such as ciclosporin, mycophenolate mofetil and tacrolimus (medicines used to suppress the immune system) may be reduced by Sevelamer carbonate Winthrop. 
mofetilmikofenolat i takrolimus (lijekovi koji se primjenjuju za potiskivanje imunološkog sustava).
Sanofi-Aventis Deutschland GmbH 
SANOFI-AVENTIS Zrt
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING LABEL - BOTTLE OF 30 TABLETS 
NALJEPNICA - BOČICA S 30 TABLETA
• indigestion, 
• probavne tegobe,
In case of constipation, please inform your doctor or pharmacist if you experience it. 
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti liječnika ili ljekarnika.
The 0.4 g dose of Sevelamer carbonate Winthrop powder must be measured using the dosing spoon provided in the carton. 
Winthrop praška mora se odmjeriti uporabom dozirne žličice koja je priložena u kutiji.
Sevelamer carbonate Winthrop is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease (CKD) not on dialysis with serum phosphorus ≥ 1.78 mmol/L. 
Sevelamer carbonate Winthrop je indiciran i za kontrolu hiperfosfatemije u odraslih bolesnika s kroničnom bubrežnom bolešću koji nisu na dijalizi, a koji imaju razinu fosfora u serumu
C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION • Periodic safety update reports (PSURs) 
• Periodička izvješća o neškodljivosti lijeka (PSURevi)
INFORMATION IN BRAILLE 17. 
15. UPUTE ZA UPORABU 16. PODACI NA BRAILLEOVOM PISMU
• stomach ache , 
• Opstrukcija crijeva
The standard dose is one tablet once a day. 
Standardna doza je jedna tableta jednom na dan.
This medicine is the same as Azilect, which is already authorised in the European Union (EU). 
Ovaj lijek isti je kao i Azilect, koji je već odobren u Europskoj uniji (EU).
The studies included 1,159 patients and lasted 26 and 18 weeks, respectively. 
Ispitivanja su obuhvatila 1.159 bolesnika i trajala su 26, odnosno 18 tjedana.
Neurotransmitters are chemicals that allow nerve cells to communicate with one another. 
Neurotransmiteri su kemikalije koje omogućuju međusobnu komunikaciju živčanih stanica.
The full EPAR and risk management plan summary for Rasagiline ratiopharm can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Cjeloviti EPAR kao i sažetak plana upravljanja rizikom za lijek Razagilin ratiopharm nalaze se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
A fall in the UPDRS score indicates an improvement in symptoms, while a rise indicates a worsening of symptoms. 
Smanjenje u vrijednosti UPDRS-a ukazuje na poboljšanje u simptomima, dok porast ukazuje na pogoršanje u simptomima.
Fluctuations happen when the effects of the medication wear off and symptoms reemerge. 
Fluktuacije se događaju prilikom slabljenja djelovanja lijeka, a simptomi se ponovno pojavljuju.
In one of the studies, a 26-week treatment with Rasagiline ratiopharm resulted in an average fall of 0.13 points in UPDRS (a standard scale for assessing symptoms of Parkinson's disease) from a starting value of 24.69 compared with a rise of 4.07 points in the patients taking placebo from a starting value of 24.54. 
U jednom od ispitivanja, 26-tjedna terapija lijekom Razagilin ratiopharm rezultirala je prosječnim smanjenjem od 0,13 poena u UPDRS-u (standardna skala za ocjenjivanje simptoma Parkinsonove bolesti) od standardne vrijednosti od 24,69 u usporedbi sa 4,07 poena u bolesnika koji su uzimali placebo od početne vrijednosti od 24,54.
They are linked to a reduction in the effect of levodopa, when the patient experiences sudden switches between being ‘on' and able to move, and being ‘off' and having difficulty moving about. 
Isti su povezani sa smanjenjem u djelovanju levodopa, u slučaju kada bolesnik osjeća iznenadne promijene između „uključenog“ stanja i sposobnosti kretanja i „isključenog“ stanja i poteškoća prilikom kretanja.
In patients with Parkinson's disease, the cells that produce dopamine die and the amount of dopamine in the brain decreases. 
U bolesnika s Parkinsonovom bolesti, stanice koje proizvode dopamin umiru, a količina dopamina u mozgu se smanjuje.
The European Commission granted a marketing authorisation valid throughout the European Union for Rasagiline ratiopharm on 12 January 2015. 
Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Razagilin ratiopharm na snazi u Europskoj uniji od 12. siječnja 2015.
It blocks the enzyme monoamine oxidase type B, which breaks down the neurotransmitter dopamine in the brain. 
Inhibira enzim monoaminooksidaze tipa B, koji razgrađuje neurotransmiter dopamin u mozgu.
Rasagiline ratiopharm is available as tablets (1 mg). 
Razagilin ratiopharm dostupan je kao tablete (1 mg).
Similar reductions in time spent in the ‘off' state were seen in patients taking entacapone. 
Slična smanjenja u vremenu provedenom u „isključenom“ stanju uočeno je u bolesnika koji su uzimali entakapon.
By increasing levels of dopamine in the parts of the brain that control movement and coordination, Rasagiline ratiopharm improves the signs and symptoms of Parkinson's disease, such as stiffness and slowness of movement. 
Povećavajući razine dopamina u dijelovima mozga koji kontroliraju pokret i koordinaciju, Razagilin ratiopharm poboljšava znakove i simptome Parkinsonove bolesti, poput ukočenosti i usporenih pokreta.
It must also not be used with pethidine (a painkiller). 
Ne smije se koristiti s petidinom (analgetikom).
In both studies, patients taking Rasagiline ratiopharm spent an average of around one hour less in the ‘off' state than those taking placebo. 
U oba ispitivanja, bolesnici koji su uzimali Razagilin ratiopharm proveli su prosječno otprilike jedan sat manje u „isključenom“ stanju u odnosu na one koji su uzimali placebo.
There should be at least 14 days between stopping treatment with Rasagiline ratiopharm and starting treatment with another monoamine-oxidase inhibitor or with pethidine. 
Treba proći najmanje 14 dana između završetka terapije lijekom Razagilin ratiopharm i početka liječenja drugim inhibitorom monoaminoksidaze ili petidinom.